Elias Jabbour
M.D. Anderson Cancer Center · MDA · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elias Jabbour as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07192237 · Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · suspended · Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT07153796 · A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · active not recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT07053059 · Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)M.D. Anderson Cancer Center · recruiting · Acute Lymphocytic Leukemia (ALL) · principal investigator
- Ph3NCT06423911 · Study of Olverembatinib (HQP1351) in Patients With CML-CPAscentage Pharma Group Inc. · recruiting · Chronic Myeloid Leukemia, CML, CML, Chronic Phase · principal investigator
- Ph1/Ph2NCT06287229 · Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabM.D. Anderson Cancer Center · recruiting · Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia · principal investigator
- Ph2NCT06236724 · Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.M.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
- Ph1NCT06088888 · TGRX-678 US Phase I for Chronic Myelogenous Leukemia PatientsShenzhen TargetRx Co., Ltd. · recruiting · Chronic Myelogenous Leukemia · principal investigator
- Ph3NCT06051409 · A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Ascentage Pharma Group Inc. · recruiting · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive · principal investigator
- Ph2NCT05007873 · ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center · active not recruiting · Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia · principal investigator
- Ph1/Ph2NCT03808610 · Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT03564678 · Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Acute Lymphoblastic Leukemia, Hyperbilirubinemia · principal investigator
- Ph2NCT03518112 · Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT03488225 · Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · principal investigator
- Ph2NCT03441061 · Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseM.D. Anderson Cancer Center · active not recruiting · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT03263572 · Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression · principal investigator
- Ph2NCT03147612 · Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1 · principal investigator
- Ph2NCT03094611 · Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02877303 · Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma · principal investigator
- Ph2NCT02689440 · Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia · principal investigator
- Ph2NCT02458014 · Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual DiseaseM.D. Anderson Cancer Center · completed · Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease · principal investigator
- Ph2NCT02199184 · Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · completed · AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · principal investigator
- Ph2NCT02159872 · Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT02141477 · Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT02135874 · Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaM.D. Anderson Cancer Center · completed · Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage · principal investigator
- Ph2NCT01746836 · Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibM.D. Anderson Cancer Center · recruiting · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph2NCT01720225 · Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01685021 · Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)MorphoSys AG · terminated · Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT01596127 · Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemM.D. Anderson Cancer Center · terminated · Leukemia, Lymphoid Malignancies, Metastatic Malignant Neoplasm to the Leptomeninges · study chair
- Ph2NCT01424982 · Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission · principal investigator
- Ph1/Ph2NCT01371630 · Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration · principal investigator
- Ph2NCT01363128 · Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaM.D. Anderson Cancer Center · completed · Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia · principal investigator
- Ph2NCT01319981 · Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01289457 · Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01019317 · Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia, AML, MDS · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03488225, NCT03094611
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:17 UTC. The ranking covers the 200 most relevant of 235 PubMed records, and a shared surname and initials can bring in a namesake. All 235 on PubMed
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.Blood · 2006398 citationsRCR 8.1
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- 331 citationsRCR 10.5
- Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.Lancet Oncol · 2012316 citationsRCR 7.7
- 298 citationsRCR 11.8
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.Cancer Discov · 2021267 citationsRCR 14.2
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Cancer · 2013255 citationsRCR 6.7